Patents by Inventor David L. Bourdet

David L. Bourdet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEZULCITINIB FOR DELIVERY BY NEBULIZED ORAL INHALATION
    Publication number: 20250288561
    Abstract: Provided herein is a method of treating a subject with a respiratory disorder when the subject is receiving high-flow oxygen through a nasal cannula, comprising administering a pharmaceutical composition comprising a therapeutic agent (such as nezulcitinib), or a pharmaceutically acceptable salt thereof, to the subject by oral nebulized inhalation.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 18, 2025
    Inventors: Nathan David PFEIFER, David L. Bourdet, Edmund J. Moran, Rajeev Saggar, Wayne Arthur Yates
  • Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
    Patent number: 12351561
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: July 8, 2025
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, R. Michael Baldwin, David L. Bourdet
  • CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF
    Publication number: 20240327360
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Application
    Filed: February 15, 2024
    Publication date: October 3, 2024
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, Gene Timothy Fass, Michael Simeone, R. Michael Baldwin, David L. Bourdet
  • METHODS FOR TREATING A SUBJECT HAVING MULTIPLE SYSTEM ATROPHY
    Publication number: 20230372318
    Abstract: Disclosed are methods for treating a subject having multiple system atrophy (MSA) using ampreloxetine or a pharmaceutically acceptable salt thereof. The methods disclosed include using ampreloxetine or a pharmaceutically acceptable salt thereof to (i) treat the symptoms of neurogenic orthostatic hypotension in a subject having MSA; (ii) reduce the magnitude of decline in the quality of life a subject having MSA; and/or (iii) increase the level of norepinephrine in a subject having MSA.
    Type: Application
    Filed: March 28, 2023
    Publication date: November 23, 2023
    Inventors: Ross VICKERY, David L. Bourdet, Tadhg Guerin, Lucy Norcliffe-Kaufmann, Beiyao Zheng
  • Crystalline (2S,4R)-5-(5?-chloro-2?-fluoro-[1,1?-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof
    Patent number: 11718591
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: August 8, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, Gene Timothy Fass, Michael Simeone, R. Michael Baldwin, David L. Bourdet
  • Administration of gut-selective JAK3 inhibitor
    Patent number: 11471442
    Abstract: Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: October 18, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Marie T. Borin, David L. Bourdet, Ai Ling Ching, Arthur Lo
  • CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF
    Publication number: 20220242836
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Application
    Filed: December 14, 2021
    Publication date: August 4, 2022
    Applicant: Theravance Biopharma R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, Gene Timothy Fass, Michael Simeone, R. Michael Baldwin, David L. Bourdet
  • ADMINISTRATION OF GUT-SELECTIVE JAK3 INHIBITOR
    Publication number: 20210353597
    Abstract: Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 18, 2021
    Inventors: Marie T. BORIN, David L. BOURDET, Ai Ling CHING, Arthur LO
  • Crystalline(2S,4R)-5-(5?-chloro-2?-fluoro-[1,1?-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
    Patent number: 10472335
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 12, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, R. Michael Baldwin, David L. Bourdet
  • CRYSTALLINE(2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENY]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF
    Publication number: 20190002416
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Application
    Filed: September 10, 2018
    Publication date: January 3, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, R. Michael Baldwin, David L. Bourdet
  • CRYSTALLINE(2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENY]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF
    Publication number: 20170275259
    Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 28, 2017
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury, Miroslav Rapta, Venkat R. Thalladi, Gene Timothy Fass, Michael Simeone, R. Michael Baldwin, David L. Bourdet